Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial-Reference-Cited by-同舟云学术

Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial

Published:2015-12 Issue:16 Volume:16 Page:1617-1629
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Gay Francesca,Oliva Stefania,Petrucci Maria Teresa,Conticello Concetta,Catalano Lucio,Corradini Paolo,Siniscalchi Agostina,Magarotto Valeria,Pour Luděk,Carella Angelo,Malfitano Alessandra,Petrò Daniela,Evangelista Andrea,Spada Stefano,Pescosta Norbert,Omedè Paola,Campbell Philip,Liberati Anna Marina,Offidani Massimo,Ria Roberto,Pulini Stefano,Patriarca Francesca,Hajek Roman,Spencer Andrew,Boccadoro Mario,Palumbo Antonio

Publisher

Elsevier BV

Subject

Oncology

Reference31 articles.

1. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma;Attal;N Engl J Med,1996

2. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma;Child;N Engl J Med,2003

3. Have drug combinations supplanted stem cell transplantation in myeloma?;Palumbo;Blood,2012

4. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial;Harousseau;J Clin Oncol,2010

5. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

Cited by 277 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tandem Autologous Stem Cell Transplantation Does Not Benefit High-Risk Myeloma Patients in the Maintenance Era: Real-World Results from The Canadian Myeloma Research Group Database;Transplantation and Cellular Therapy;2024-09

2. The emerging role of melflufen and peptide-conjugates in multiple myeloma;Current Opinion in Oncology;2024-08-22

3. Historical Perspective of High-Dose Therapy Followed by Autologous Stem Cell Transplantation in Multiple Myeloma;Acta Haematologica;2024-05-06

4. SOHO State of the Art Updates and Next Questions: Will CAR-T Replace ASCT in NDMM;Clinical Lymphoma Myeloma and Leukemia;2024-05

5. Treatment pattern and outcomes of re-induction therapy prior to stem cell transplantation in patients with relapsed/refractory multiple myeloma in Germany;Bone Marrow Transplantation;2024-03-14